(July 23, 2015) New OCRF-funded research demonstrates that combining a PARP-inhibitor with immune therapy results in tumor rejection and long-term survival in a mouse model of BRCA1-deficient ovarian cancer. The study, published in Cancer Immunology Research, was funded by an OCRF Liz Tilberis Early Career Award to Sarah Adams, MD.
The benefit of this combination depends on changes in immune cell function specifically in the peritoneal tumor environment which promote the establishment of protective immune memory. In addition, cytokines produced by local T cells in response to this regimen improve tumor cell killing by the PARP-inhibitor. A similar increase in tumor cell death in human BRCA1- cancer cells in vitro suggests that this regimen could benefit patients with hereditary tumors.
Read the abstract here.
